{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:40:05Z","timestamp":1750538405103,"version":"3.41.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Peptide receptor radionuclide therapy (PRRT) with <jats:sup>177<\/jats:sup>Lu-DOTATATE has shown great treatment efficacy in patients with well-differentiated metastatic neuroendocrine tumors and a metastatic size reduction of ~20% for metastatic lesions &lt;3 cm in size. We present a 66-year-old man with pancreatic neuroendocrine carcinoma, who had a rapidly growing metastatic nodal conglomerate, which measured close to 10 cm in size. After only 2 cycles of PRRT with <jats:sup>177<\/jats:sup>Lu-DOTATATE, the nodal conglomerate had a striking size reduction greater than 75%. This case highlights the potential efficacy of PRRT with <jats:sup>177<\/jats:sup>Lu-DOTATATE for treatment of aggressive neuroendocrine neoplasms.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004262","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T14:03:11Z","timestamp":1655128991000},"page":"961-962","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177Lu-DOTATATE"],"prefix":"10.1097","volume":"47","author":[{"given":"Eduardo A.","family":"Somoza","sequence":"first","affiliation":[{"name":"Department of Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heying","family":"Duan","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shagufta","family":"Shaheen","sequence":"additional","affiliation":[{"name":"Department of Medicine-Medical Oncology, Stanford University, Stanford, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Medicine-Medical Oncology, Stanford University, Stanford, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina Mari","family":"Aparici","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,11]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing but NET: a review of neuroendocrine tumors and carcinomas","volume":"19","year":"2017","journal-title":"Neoplasia"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/RLU.0000000000002646","article-title":"Efficacy of 177Lu peptide receptor radionuclide therapy for the treatment of neuroendocrine tumors: a meta-analysis","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","article-title":"Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-DOTATATE: an analysis of the NETTER-1 study","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cncr.28721","article-title":"Gastroenteropancreatic high-grade neuroendocrine carcinoma","volume":"120","year":"2014","journal-title":"Cancer"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/PAS.0000000000000169","article-title":"Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases","volume":"38","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.soc.2019.11.005","article-title":"Overview and current status of peptide receptor radionuclide therapy","volume":"29","year":"2020","journal-title":"Surg Oncol Clin N Am"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1530\/ERC-18-0424","article-title":"Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study","volume":"26","year":"2019","journal-title":"Endocr Relat Cancer"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:03:33Z","timestamp":1750536213000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,11]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004262","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2022,6,11]]}}}